Trial results show promising insights into the potential of retatrutide for addressing obesity and various weight-related conditions: In patients with type 2 diabetes (T2D) and obesity, subcutaneous administration of retatrutide for 12 weeks resulted in reductions in body weight of up to 8.96 kg with a safety and tolerability profile similar to other incretins (weight loss peptides)
The consultation includes medical-history review, current-medication review, lab review, candidacy evaluation, and selection of the appropriate semaglutide product (Ozempic, Wegovy, or compounded semaglutide)
Using a SingleCare coupon for a generic liraglutide prescription for weight loss can save you up to 70% without insurance
18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial
A surprising number say theyre sleeping more overall, which may increase the chance of remembering dreams